A Phase 2 interventional study of Rotigotine and Rotigotine in Fibromyalgia Syndrome, sponsored by UCB Pharma. Completed at 35 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.
Among the 369 studies in Fibromyalgia with a site in United States, this one is the 70th largest by enrollment of the 320 interventional ones that give a count, is one of 17 that started in 2007, is one of 44 in phase 2, and was the 60th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 14–26
Spaulding Rehabilitation Hospital · Sites in United States
Ages 21–65
Pulkit Grover · Sites in United States
Ages 18–65
Theranica · Sites in United States, Israel
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 61 · Phase 3 64 · Phase 4 24
First in 1994; this study’s year is marked. 17 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 72 across the 320 interventional studies, 200 across the 47 observational. Of the 276 that completed or were terminated, 116 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 369 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
29 of the studies in Fibromyalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT07116278University of California, San FranciscoTMS-EEG Biomarkers for Chronic Pain | 2026-12 |
| NCT04949100Paul CrawfordMicrocurrent for Fibromyalgia | 2026-12 |
| NCT07525063Duke UniversityPain & Reward Neuromodulation of CNS Circuits | 2026-12 |
| NCT06552728University of California, IrvineThe Effects of Energy Healing in Fibromyalgia | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 369 studies in Fibromyalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is to investigate the efficacy and safety of rotigotine as compared to placebo in reducing signs and symptoms of fibromyalgia syndrome. The effects of rotigotine on pain, sleep, general activity, mood, and quality of life, and the use of rescue medication to treat pain will be assessed.
The overall post-Baseline duration of treatment was 13 weeks. The trial consisted of a 4-week Titration Phase, an 8-week Maintenance Phase, a 1-week De-escalation Phase, and a 2-week Safety Follow-Up Phase. If subjects met the eligibility criteria, they were randomized to receive rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or placebo during the Maintenance Phase. During the 4-week Titration Phase, subjects assigned to rotigotine were titrated at weekly intervals of 2 mg/24 hrs until they reached 4 mg/24 hrs or 8 mg/24 hrs. All subjects who completed the 4-week Titration Phase entered an 8-week Maintenance Phase and were maintained at their randomized dose (rotigotine 4 mg/24 hrs, rotigotine 8 mg/24 hrs, or placebo). No dose adjustment was allowed during the Maintenance Phase. The Treatment Phase was defined as the combined Titration and Maintenance Phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Other: Placebo
4 mg/24 hrs
Drug: Rotigotine
8 mg/24 hrs
Drug: Rotigotine
Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
Also known as: Neupro
Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
Also known as: Neupro
Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set)
The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).
Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase
Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set)
The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).
Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase
Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase
The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Change From Baseline in Total Myalgic Score to the Last Assessment in the 12-week Treatment Phase
Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase
Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)
Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase
Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase
General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)
Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase
Patient Global Impression of Change (PGIC) Assessment From Baseline to the Last Assessment in the 12-week Treatment Phase
The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse \[score of 1\] to much better \[score of 7\]).
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Change From Baseline in Morning and Evening Pain Scores to the Last 2 Weeks of the 12-week Treatment Phase
An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).
Time frame: Baseline, Last 2 weeks of the 12-week Treatment Phase
Number of Subjects Using Rescue Medication and Alcohol During the 12-week Treatment Phase
Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.
Time frame: 12-week Treatment Phase
Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12
Time frame: End of the Maintenance Phase/Week 12
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Scores to the Last Assessment in the 12-week Treatment Phase
The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Change From Baseline in Fibromyalgia Symptom Scores to the Last Assessment in the 12-week Treatment Phase
All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Change From Baseline in Beck Depression Inventory-II (BDI-II) Scores to the Last Assessment in the 12-week Treatment Phase
The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.
Time frame: Baseline, Last assessment in the 12-week Treatment Phase
Number of Subjects With Presence of Impulse Control Disorders
Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).
Time frame: 12-week Treatment Phase
The Full Analysis Set (FAS) contains all randomized subjects who received at least 1 dose of trial medication, and had at least 1 post-Baseline Likert pain score. The Per Protocol Set contains all subjects in the FAS who completed at least 2 weeks of the Maintenance Phase and had no major protocol deviations.
| Milestone | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Started | 82 | 74 | 74 |
| Completed | 50 | 42 | 19 |
| Not completed | 32 | 32 | 55 |
| Withdrew: Adverse event | 12 | 17 | 33 |
| Withdrew: Lack of efficacy | 7 | 7 | 4 |
| Withdrew: Withdrawal by subject | 5 | 3 | 5 |
| Withdrew: Protocol violation | 1 | 1 | 5 |
| Withdrew: Non-compliance | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 5 | 2 | 5 |
| Withdrew: Other: subject's schedule doesn't permit | 1 | 0 | 0 |
| Withdrew: Other: subject left town; family illness | 1 | 0 | 0 |
| Withdrew: Other: study demands too great | 0 | 1 | 0 |
| Withdrew: Other: personal family reasons | 0 | 0 | 1 |
| Withdrew: Other: subject's disability per sponsor | 0 | 0 | 1 |
The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).
| Score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set) | -1.12 ± 1.83 | -1.27 ± 1.86 | -0.83 ± 1.70 |
The Fibromyalgia Impact Questionnaire (FIQ) Total Score ranges from 0 to 100 with higher scores corresponding to a greater impact of fibromyalgia
| Score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) Total Score to the Last Assessment in the 12-week Treatment Phase | -14.9 ± 15.6 | -13.4 ± 13.7 | -12.8 ± 18.1 |
Total Myalgic Score ranges from 0 to 54 with higher scores corresponding to a greater level of pain.
No measurements were reported for this outcome.
Sleep scale - the subject rated quality of sleep, from 0 (very good sleep) to 10 (very poor sleep)
| Score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Change From Baseline in Average Daily Interference With Sleep to the Last 2 Weeks of the 12-week Treatment Phase | -0.95 ± 2.01 | -0.82 ± 2.03 | -0.48 ± 2.09 |
General activity scale - the subject rated how the pain had interfered with general activity, from 0 (did not interfere) to 10 (completely interfered)
| Score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Change From Baseline in Daily Interference With General Activity to the Last 2 Weeks of the 12-week Treatment Phase | -1.11 ± 2.05 | -1.19 ± 1.82 | -0.88 ± 2.10 |
The PGIC is a 7-point self-administered categorical rating scale in which the subject rated the change in pain since starting trial medication (from much worse \[score of 1\] to much better \[score of 7\]).
| Patients | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Much better | 8 | 10 | 9 |
| Moderately better | 14 | 14 | 7 |
| Mildly better | 25 | 12 | 11 |
| No change | 16 | 17 | 12 |
| Mildly worse | 5 | 3 | 5 |
| Moderately worse | 7 | 1 | 5 |
| Much worse | 1 | 1 | 2 |
An 11-point Likert scale was used for subjects to assess pain, from 0 (no pain) to 10 (worst pain ever experienced).
| Score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Morning Pain Score | -1.07 ± 1.91 | -1.30 ± 1.91 | -0.78 ± 1.78 |
| Evening Pain Score | -1.17 ± 1.82 | -1.24 ± 1.90 | -0.88 ± 1.89 |
Subjects recorded use of rescue medication for pain in the diary daily in the evening with a Yes/No response. Use of alcohol to treat pain in the past 24 hours was recorded with a Yes/No response.
No measurements were reported for this outcome.
| ug/ML | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Rotigotine Plasma Concentration at the End of the Maintenance Phase/Week 12 | — | 0.2388 ± 0.2337 | 0.2981 ± 0.2973 |
The Hospital Anxiety and Depression Scale (HADS) is a self-administered instrument for detecting anxiety and depression in medical outpatients. Scores range from 0 to 21 for each subscale with higher scores reflecting a greater level of anxiety or depression.
No measurements were reported for this outcome.
All scores range from 0 to 10 with higher scores corresponding to a greater level of symptom severity.
No measurements were reported for this outcome.
The Beck Depression Inventory-II is a 21-item questionnaire. Each item is scored on a scale of 0 to 3 with a total score ranging from 0 to 63. A higher total score is associated with more severe depressive symptoms.
No measurements were reported for this outcome.
Impulse control disorders (ICDs) are a set of psychiatric disorders in which a person is unable to control strong and often harmful impulses. They are assessed in this study using the Jay Modified Minnesota Impulsive Disorders Interview (Jay Modified MIDI), which focuses on the five most common ICDs that may be associated with dopamine agonist use: compulsive buying, compulsive gambling, compulsive eating, hypersexuality and punding (performing repetitive and/or mechanical tasks).
No measurements were reported for this outcome.
The average daily pain score is calculated using an 11-point Likert scale, ranging from 0 (no pain) to 10 (worst pain ever experienced).
| score on a scale | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Per Protocol Set) | -1.28 ± 1.79 | -2.09 ± 2.07 | -1.57 ± 2.27 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 4/82 (4.9%) | 53/82 (64.6%) |
| Rotigotine 4 mg | — | 1/73 (1.4%) | 55/73 (75.3%) |
| Rotigotine 8 mg | — | 1/74 (1.4%) | 65/74 (87.8%) |
| Event | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| Chest painGeneral disorders | 0/82 | 1/73 | 0/74 |
| CholelithiasisHepatobiliary disorders | 0/82 | 0/73 | 1/74 |
| PneumoniaInfections and infestations | 1/82 | 0/73 | 0/74 |
| Ankle fractureInjury, poisoning and procedural complications | 1/82 | 0/73 | 0/74 |
| Lung injuryInjury, poisoning and procedural complications | 1/82 | 0/73 | 0/74 |
| Rib fractureInjury, poisoning and procedural complications | 1/82 | 0/73 | 0/74 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/82 | 0/73 | 0/74 |
| Intracranial hypotensionNervous system disorders | 1/82 | 0/73 | 0/74 |
| Nerve compressionNervous system disorders | 1/82 | 0/73 | 0/74 |
| Trigeminal neuralgiaNervous system disorders | 1/82 | 0/73 | 0/74 |
| Event | Placebo | Rotigotine 4 mg | Rotigotine 8 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 18/82 | 34/73 | 48/74 |
| VomitingGastrointestinal disorders | 1/82 | 13/73 | 18/74 |
| HeadacheNervous system disorders | 12/82 | 13/73 | 12/74 |
| Application site pruritusGeneral disorders | 4/82 | 3/73 | 11/74 |
| DizzinessNervous system disorders | 6/82 | 10/73 | 8/74 |
| SomnolenceNervous system disorders | 6/82 | 8/73 | 7/74 |
| DiarrhoeaGastrointestinal disorders | 6/82 | 5/73 | 8/74 |
| Upper respiratory tract infectionInfections and infestations | 1/82 | 7/73 | 2/74 |
| Dry mouthGastrointestinal disorders | 3/82 | 5/73 | 7/74 |
| InsomniaPsychiatric disorders | 4/82 | 6/73 | 7/74 |
| Age, Categorical(Participants) | Placebo | Rotigotine 4 mg | Rotigotine 8 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 81 | 73 | 73 | 227 |
| >=65 years | 1 | 0 | 1 | 2 |
| Age, Continuous(years) | Placebo | Rotigotine 4 mg | Rotigotine 8 mg | Total |
|---|---|---|---|---|
| Mean | 46.4 ± 10.7 | 47.5 ± 10.3 | 47.0 ± 11.6 | 47.0 ± 10.8 |
| Sex: Female, Male(Participants) | Placebo | Rotigotine 4 mg | Rotigotine 8 mg | Total |
|---|---|---|---|---|
| Female | 76 | 65 | 68 | 209 |
| Male | 6 | 8 | 6 | 20 |
| Region of Enrollment(participants) | Placebo | Rotigotine 4 mg | Rotigotine 8 mg | Total |
|---|---|---|---|---|
| United States | 82 | 73 | 74 | 229 |
The record gives a start of Mar 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine